BRIEF-Janssen Says Darzalex Combination Regimen Shows Improved Outcomes
December 12, 2017 at 11:44 AM EST
* JANSSEN - DARZALEX (DARATUMUMAB) COMBINATION REGIMEN SIGNIFICANTLY IMPROVED OUTCOMES FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS TRANSPLANT INELIGIBLE Source text for Eikon: Further company coverage: